1. Home
  2. ALTI vs ZURA Comparison

ALTI vs ZURA Comparison

Compare ALTI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AlTi Global Inc.

ALTI

AlTi Global Inc.

HOLD

Current Price

$3.62

Market Cap

396.5M

Sector

Finance

ML Signal

HOLD

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$5.21

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTI
ZURA
Founded
2020
2022
Country
United States
United States
Employees
490
40
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.5M
455.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ALTI
ZURA
Price
$3.62
$5.21
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$13.00
AVG Volume (30 Days)
274.5K
1.7M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
41.11
N/A
EPS
N/A
N/A
Revenue
$254,956,000.00
N/A
Revenue This Year
$18.06
N/A
Revenue Next Year
$10.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.21
N/A
52 Week Low
$2.75
$1.26
52 Week High
$5.45
$7.25

Technical Indicators

Market Signals
Indicator
ALTI
ZURA
Relative Strength Index (RSI) 55.53 56.97
Support Level $3.27 $4.22
Resistance Level $3.93 $5.88
Average True Range (ATR) 0.25 0.55
MACD 0.05 0.08
Stochastic Oscillator 61.54 65.09

Price Performance

Historical Comparison
ALTI
ZURA

About ALTI AlTi Global Inc.

AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Share on Social Networks: